"We are a member site of ENCORE Research Group, a premier clinical research organization that has conducted more than 2,500 clinical trials over 20 years and has worldwide recognition for providing patients access to cutting edge medical research. If you have a medical issue and want a research solution, or if you are a healthy volunteer, come visit our center and learn more. One of our experts will be happy to evaluate you."

During the past decade, ENCORE Borland-Groover Clinical Research conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 7 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 7 clinical trials were completed. i.e. 46.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ENCORE Borland-Groover Clinical Research" #1 sponsor was "Phathom Pharmaceuticals, Inc." with 4 trials, followed by "Shire" with 3 trials sponsored, "Celgene" with 2 trials sponsored, "Gilead Sciences" with 2 trials sponsored and "Medtronic - MITG" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ENCORE Borland-Groover Clinical Research" #1 collaborator was "Novo Nordisk A/S" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "ENCORE Borland-Groover Clinical Research" are "Ulcerative Colitis" (5 trials), "Eosinophilic Esophagitis" (3 trials), "Heartburn" (2 trials), "Non-Erosive Gastro-Esophageal Reflux Disease" (2 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "ENCORE Borland-Groover Clinical Research" in a lesser frequency.

Most popular intervention types in "ENCORE Borland-Groover Clinical Research" are "Drug" (17 trials), "Other" (3 trials), "Biological" (1 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Vonoprazan" (4 trials), "CC-93538" (2 trials), "Lansoprazole" (2 trials) and "Ontamalimab" (2 trials). Other intervention names were less common.

The vast majority of trials in "ENCORE Borland-Groover Clinical Research" are 21 trials for "All" genders.

Currently, there are NaN active trials in "ENCORE Borland-Groover Clinical Research". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in ENCORE Borland-Groover Clinical Research, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in ENCORE Borland-Groover Clinical Research, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".